As the director of addiction psychiatry at NYU Langone Medical Center, Stephen Ross spends most of his time helping people quit drugs. But early next year, he will begin administering MDMA in his “dosing room,” a chamber in Dr. Ross’s medical research lab that resembles a comfortable living room, with a gong on the wall and ceramic mushrooms decorating the shelves. After ingesting a 125-milligram capsule of the drug, a patient will recline on a brown felt couch as Dr. Ross and a co-therapist conduct an eight-hour talk-therapy session.
MDMA, aka ecstasy, will still be an illegal drug when Dr. Ross begins these sessions. But it’s emerging as one of the most promising treatments for intractable post-traumatic stress disorder. In Phase II clinical trials, which ended in November 2016, more than two-thirds of patients attained “sustained remission” of their PTSD after three MDMA-assisted therapy sessions. Based on those results, …
READ MORE ON WSJ.COM